

**ciclesonide 80mcg, 160mcg inhaler (Alvesco®) No. (412/07)**  
**Altana Pharma Ltd**

Product Update

5 October 2007

The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**ciclesonide inhaler (Alvesco®)** is accepted for use within NHS Scotland at high doses (up to 640mcg daily for up to 12 weeks) to control persistent asthma in adolescents and adults (12 years and older).

The higher dose should be used in patients for whom ciclesonide is an appropriate choice of maintenance inhaled corticosteroid therapy. Alternative inhaled steroids are available at lower costs.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 10 August 2007.*

**Chairman,  
Scottish Medicines Consortium**